Renal Cell AREN1721

A Randomized Phase 2 Trial of Axitinib / Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE / Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

Back To Clinical Trials NCI Database Entry